COPD trial run by a global, science-led biopharmaceutical company that spans the discovery, development, manufacturing, distribution and worldwide commercialisation of medicines.
The DynaPort MoveMonitor was used in a Phase IV pharmaceutical trial to search for the efficacy of a COPD drug.
For this multicentre and multinational clinical trial 268 patients were randomized.
Secondary Objectives included evaluating the effect of the medication on exercise capacity and physical activity before and after behavioral intervention compared with placebo in patients with COPD.
The MoveMonitor was worn continuously day and night during at least 7 days to measure the physical activity of the patient.
The efficacy of the drug was assessed by means of the following tests and parameters: the physical activity parameters and the PROactive questionnaire were collected by means of the MoveMonitor and the e-diary respectively.
Parameters collected with the MoveMonitor: